The global transfection reagents & equipment market size is expected to reach USD 1.4 billion by 2025, expanding at a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The latest polymeric formulations-based compounds are gentle to cells as compared to cationic liposomes and these products render higher gene-delivery efficiency, further promoting the development of unique transfection products in the market.
Moreover, multi-component reagents such as X-tremeGENE provided by F. Hoffmann-La Roche AG, deliver high efficiency and minimal cytotoxicity than traditional ones comprising only one-component formulations. Thus, companies are keen on offering cutting-edge transfection solutions, in turn, offering significant momentum to market growth.
The gene expression studies segment dominated the market and account for the largest revenue share in 2019. This is attributed to the rising focus on the translation of genomic information in clinics. In addition, an increasing number of research projects related to the identification of chromosomal anomalies is anticipated to propel segment growth.
Request a free sample copy or view report summary: Transfection Reagents & Equipment Market Report
The reagents segment accounted for the highest revenue of USD 465.9 million in 2019 and is anticipated to maintain this trend throughout the forecast period
This is attributed to the heavy investments by manufacturers including F. Hoffmann-La Roche AG in the development of multicomponent-based products
Lipofection is emerging as a lucrative technique, which can be attributed to its wide acceptance across sequential, reverse, multiple, transient, and co-transfection
Moreover, high protocol variability allows lipofection to be used for transfection of all types of nucleic acids and also contributes to the revenue generation by this segment
Biomedical research includes the application of transfection reagents across mutational analysis, library screening, and preclinical testing. This segment is estimated to witness the fastest growth rate of more than 8.0% during the study period
North America generated maximum revenue of 40.0% in 2019 attributed to the sufficient presence of skilled professionals along with the strong network of original equipment manufacturers
Market participants are keen on expanding their product portfolios aimed at sustaining market competition
For instance, in July 2019, Mirus Bio launched TransIT-VirusGEN SELECT Transfection Reagent, intended to be used in the drug discovery process in gene and cell manufacturing. The substance simplifies the qualifying process of ancillary materials employed in viral vectors manufacturing for preclinical and early-phase clinical trials.
Grand View Research has segmented the global transfection reagents and equipment market on the basis of product, method, application, and region:
Transfection Reagents & Equipment Product Outlook (Revenue, USD Million, 2014 - 2025)
Reagents
Equipment
Transfection Reagents & Equipment Method Outlook (Revenue, USD Million, 2014 - 2025)
Electroporation
Liposomes
Particle Bombardment
Microinjection
Adenoviral Vectors
Calcium Phosphate
DEAE-dextran
Magnetic Beads
Activated Dendrimers
Laserfection
Transfection Reagents & Equipment Application Outlook (Revenue, USD Million, 2014 - 2025)
Gene Expression Studies
Protein Production
Transgenic Models
Therapeutic Delivery
Cancer Research
Biomedical Research
Transfection Reagents & Equipment Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
The U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
MEA
South Africa
List of Key Players of Transfection Reagents & Equipment Market
Thermo Fisher Scientific, Inc.
Promega Corporation
Lonza
QIAGEN
F. Hoffmann-La Roche Ltd.
Bio-Rad Laboratories Inc.
Merck KGaA
OriGene Technologies Inc.
MaxCyte, Inc.
POLYPLUS TRANSFECTION
Horizon Discovery Ltd.
PromoCell GmbH.
"The quality of research they have done for us has been excellent..."